MaaT Pharma presented positive results from the Early Access Program in Europe involving 111 patients with steroid-refractory or steroid-dependent gastrointestinal acute graft-versus-host Disease treated with MaaT013, at the 2023 American Society of Hematology Annual Meeting.
